Amongst people with HF, up to 50% are estimated to have type 2 diabetes and, vice versa, around 20% of the over 500 million people living with type 2 diabetes have been shown to have comorbid HF (ClinicalTrials.gov IDs NCT04916470 and NCT04788511), it may be relevant to consider obesity-related HFpEF as a specific (sub)phenotype, whether coexisting with type 2 diabetes or not
Beta Blocker Rebound Phenomenon Is Important, But We Do Not Know Its Definition, Incidence or Optimal Prevention Strategies
All purchases are limited to licensed researchers and/or qualified professionals
some weaning patients After losing 50 pounds on the injectable weight loss medication Zepbound, Kyra Wensley received a surprising letter from her pharmacy benefit manager in April
The Safety Question: Thyroid Cancer and GLP-1s One of the most common concerns regarding GLP-1 medications is the "black box" warning often found on the packaging regarding thyroid cancer